Regeneron Pharmaceuticals, Inc. REGN
What this company does
Written from the business description in REGENERON PHARMACEUTICALS, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 4 February 2026. Every sentence was checked against that document before publication.
Revenue compounded at +11.0% a year over five years — but profit grew slower: net income at +5.1%, earnings per share at +6.3%.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity produced 15 cents of profit this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 14.3 | 14.2 | 13.1 | 12.2 | 16.1 | 8.5 | 6.6 | 5.1 | 5.9 | 4.9 | 4.1 | 2.8 | 2.1 | 1.4 | 0.4 | 0.5 | 0.4 | 0.2 |
| Operating income $B | 3.6 | 4.0 | 4.0 | 4.7 | 8.9 | 3.6 | 2.2 | 2.5 | 2.1 | 1.3 | 1.3 | 0.8 | 0.7 | 0.5 | −0.2 | −0.1 | −0.1 | −0.1 |
| EBITDA $B | 4.1 | 4.5 | 4.5 | 5.1 | 9.2 | 3.8 | 2.4 | 2.7 | 2.2 | 1.4 | 1.3 | 0.9 | 0.8 | 0.5 | −0.2 | −0.1 | −0.1 | −0.1 |
| Income tax $B | 0.7 | 0.4 | 0.2 | 0.5 | 1.3 | 0.3 | 0.3 | 0.1 | 0.9 | 0.4 | 0.6 | 0.4 | 0.3 | −0.3 | −0.0 | 0.0 | −0.0 | 0.0 |
| Net income $B | 4.5 | 4.4 | 4.0 | 4.3 | 8.1 | 3.5 | 2.1 | 2.4 | 1.2 | 0.9 | 0.6 | 0.3 | 0.4 | 0.8 | −0.2 | −0.1 | −0.1 | −0.1 |
| Free cash flow $B | 4.1 | 3.7 | 3.9 | 4.4 | 6.5 | 2.0 | 2.0 | 1.8 | 1.0 | 1.0 | 0.7 | 0.4 | 0.4 | −0.1 | −0.2 | −0.0 | −0.2 | −0.1 |
| EPS, diluted $ | 41.48 | 38.34 | 34.77 | 38.22 | 71.97 | 30.52 | 18.46 | 21.29 | 10.34 | 7.70 | 5.52 | 2.98 | 3.72 | 6.75 | −2.45 | −1.26 | −0.85 | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | 8 | 0 | 0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | 14.9 | 16.0 | 16.3 | 20.9 | 54.2 | 31.8 | 21.3 | 32.8 | 22.6 | 22.1 | 20.5 | 15.0 | 25.7 | 86.1 | −43.8 | −22.6 | −16.6 | −18.8 |
| Shares out B | · | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | · | · | 0.09 | 0.00 | 0.08 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 18 of 19 fiscal years. 15 checks could not be computed.